ADCT Adc Therapeutics SA
Price (delayed)
$3.09
Market cap
$298.64M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.57
Enterprise value
$121.5M
adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.
Highlights
Adc Therapeutics's quick ratio has increased by 37% from the previous quarter and by 21% YoY
Adc Therapeutics's equity has increased by 32% from the previous quarter
The company's net income fell by 18% YoY but it rose by 5% QoQ
Adc Therapeutics's EPS has decreased by 12% YoY but it has increased by 8% QoQ
The gross profit has plunged by 66% YoY and by 3% from the previous quarter
The revenue has plunged by 64% YoY and by 2.7% from the previous quarter
Key stats
What are the main financial stats of ADCT
Market
Valuations
Earnings
Shares outstanding
96.65M
Market cap
$298.64M
Enterprise value
$121.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.82
Revenue
$66.75M
EBIT
-$124.49M
EBITDA
-$121.01M
Free cash flow
-$151.26M
Per share
Balance sheet
Liquidity
EPS
-$2.57
Free cash flow per share
-$1.58
Book value per share
-$1.59
Revenue per share
$0.7
TBVPS
$3.89
Total assets
$371.78M
Total liabilities
$503.45M
Debt
$122.98M
Equity
-$131.67M
Working capital
$297.73M
Debt to equity
-0.93
Current ratio
6.17
Quick ratio
5.6
Net debt/EBITDA
1.46
Margins
Efficiency
Dividend
EBITDA margin
-181.3%
Gross margin
93.5%
Net margin
-324.6%
Operating margin
-205.7%
Return on assets
-57.7%
Return on equity
N/A
Return on invested capital
-84.2%
Return on capital employed
-39.6%
Return on sales
-186.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADCT stock price
How has the Adc Therapeutics stock price performed over time
Intraday
-0.32%
1 week
12.36%
1 month
10.75%
1 year
276.83%
YTD
86.14%
QTD
-2.22%
Financial performance
How have Adc Therapeutics's revenue and profit performed over time
Revenue
$66.75M
Gross profit
$62.4M
Operating income
-$137.28M
Net income
-$216.66M
Gross margin
93.5%
Net margin
-324.6%
The gross profit has plunged by 66% YoY and by 3% from the previous quarter
The revenue has plunged by 64% YoY and by 2.7% from the previous quarter
Adc Therapeutics's operating income has decreased by 33% YoY but it has increased by 7% QoQ
The company's net income fell by 18% YoY but it rose by 5% QoQ
Growth
What is Adc Therapeutics's growth rate over time
Valuation
What is Adc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
4.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.82
Adc Therapeutics's EPS has decreased by 12% YoY but it has increased by 8% QoQ
Adc Therapeutics's equity has increased by 32% from the previous quarter
The revenue has plunged by 64% YoY and by 2.7% from the previous quarter
ADCT's price to sales (P/S) is 43% higher than its last 4 quarters average of 3.1
Efficiency
How efficient is Adc Therapeutics business performance
Adc Therapeutics's return on sales has shrunk by 134% YoY but it has increased by 11% QoQ
The ROA has plunged by 56% YoY and by 3% from the previous quarter
The return on invested capital has declined by 6% year-on-year but it has increased by 6% since the previous quarter
Dividends
What is ADCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADCT.
Financial health
How did Adc Therapeutics financials performed over time
Adc Therapeutics's total assets is 26% less than its total liabilities
Adc Therapeutics's quick ratio has increased by 37% from the previous quarter and by 21% YoY
ADCT's current ratio is up by 34% since the previous quarter and by 21% year-on-year
Adc Therapeutics's debt is 193% higher than its equity
The debt to equity has soared by 94% YoY but it has contracted by 48% from the previous quarter
Adc Therapeutics's equity has increased by 32% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.